A leading cancer center on Friday prevailed in a lawsuit seeking to add its researcher’s name to patents for a form of cancer immunotherapy, a decision that will allow it to license the intellectual property behind the patents to companies developing new therapies.

A U.S. District Court judge ruled in favor of the Dana-Farber Cancer Institute on all six counts on which it was challenging the patents, which underlie the blockbuster cancer drug Opdivo.  

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The thought that any corporation would not allow any patients who are amongst those who have benefited from a protocol, to help them to get rid of cancer, is not a corporation that should be allowed to receive this treatment of the only way patients have been able to resume their lives, is a corporation that is not helping patients who don’t go to one place only, is unethical and needs to be stopped, in my opinion.

    Another example of profits over patients. That type of corporation is not one to be accountable for their incomprehensible approach to the individuals who are benefiting from the treatment.

    No one else should ever be unable to access the best way to get rid of cancer. Especially when one corporation wants to keep it from being accessible by other hospitals and treatment centers.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy